The Federal Circuit upheld a district court’s invalidation of four patents asserted against Google LLC and Apple Inc. that ...

On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:ANIX) breast cancer vaccine technology.

The US does not fear failing. Failing for the US is the first attempt to success," he said. The European Patent Organisation has 39 members including Turkey and Norway. It receives around ...

Patent covers α-lactalbumin-based immunization method for breast cancer. Cleveland Clinic licensed the vaccine tech exclusively to Anixa. Today's manic market swings are creating the perfect ...

The application was assigned patent number US 2025/0100558 A1 with the United States Patent and Trademark Office (USPTO) and was published on March 27 th, 2025. The GM patent application was ...

"These patent applications strengthen our IP portfolio as we advance on our mission transform the standard of care for obesity and break into the animal health market.” EL-32 USA US 18/627,462 ...

NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the ...

The United States Patent and Trademark Office (USPTO), acting as the International Search Authority, has issued a favourable written opinion on all claims in INmune Bio’s international patent ...

The company reaffirmed its 2025 financial guidance, despite a slight decline in Q1 sales and ongoing patent litigation with ... though it underperformed the broader US market's 5.9% return in ...

AMD advances US chip strategy with TSMC, joining Nvidia in massive domestic shift Taiwan’s Mastertrans readies fast-charging intercity e-bus CloudMile outlines 3 keys to unlock JS-SEZ potential ...

IT major Mphasis said on Wednesday said it has received an award of a US patent on “System and method for optimized processing of information on quantum systems”. However, unfazed by the ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...